exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089295 RNA Name: hsa-miR-663a RNA Type: miRNA Chromosome: chr20 Starnd: - Coordinate: Start Site(bp): 26208243 End Site(bp): 26208264 External Links: hsa-miR-663a

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand COL6A2 chr21 46098112 46132848 + KLC2 chr11 66257294 66267860 + REXO1 chr19 1815248 1848483 - MIDN chr19 1248553 1259140 + STK35 chr20 2101827 2177038 + MIGA2 chr9 129036621 129072082 + SRPRA chr11 126262938 126269144 - KDM2A chr11 67119263 67258082 + JUNB chr19 12791486 12793315 + GNB1 chr1 1785285 1891117 - SYVN1 chr11 65121780 65134533 - SCN1B chr19 35030470 35040449 + SMAD3 chr15 67063763 67195169 + HIF1AN chr10 100529072 100559998 + TNRC6A chr16 24610209 24827632 + ARHGAP1 chr11 46677080 46700619 - ARL8A chr1 202133404 202144743 - PPDPF chr20 63520765 63522206 + KMT5A chr12 123383773 123409353 + RTL8A chrX 135050932 135052196 - SOX12 chr20 325595 330224 + CYB5R3 chr22 42617840 42649392 - PRR12 chr19 49591182 49626439 + CAPN15 chr16 527712 554636 + DMWD chr19 45782947 45792845 - BOC chr3 113211003 113287459 + FAM83H chr8 143723933 143738234 - CLSTN1 chr1 9728926 9823984 - CALR chr19 12938578 12944489 + CMIP chr16 81445170 81711762 + miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC008738.7 chr19 33207129 33207639 + AC020928.2 chr19 36773712 36775908 - AC069281.2 chr7 100572232 100578700 - AC234582.1 chr1 155195004 155205495 + AL137127.1 chr1 19072110 19075511 - AL355075.4 chr14 20343048 20343685 - AL356488.2 chr1 109100193 109100619 + GAS5 chr1 173858559 173868882 - MIR663AHG chr20 26167817 26251546 - NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG25 chr17 64145970 64146476 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.